A retrospective case report series of patients (post-marketing) Receiving Olanzapine IntraMuscular Outside of Product Monograph doses and indications: assessing safety and tolerability
Completed
- Conditions
- Various mental disorders under Diagnostic and Statistical Manual of mental disorders fourth edition (DSM-IV)Mental and Behavioural Disorders
- Registration Number
- ISRCTN76803177
- Lead Sponsor
- ondon Health Sciences Centre (Canada)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients whom have received Olanzapine IM in doses exceeding doses stated in literature or for uses not listed in the current edition of the Compendium of Pharmaceuticals and Specialties.
Exclusion Criteria
Patients under 16 or over 70 years of age, or those whom have a documented allergy or sensitivity to olanzapine, also patients whom have used the olanzapine IM within normal dosing parameters.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method